Premium
Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non‐small cell carcinoma results from a randomized phase II trial
Author(s) -
Dautzenberg Bertrand,
Benichou Jacques,
Allard Philippe,
Lebeau Bernard,
Coetmeur Daniel,
Brechot JeanneMarie,
Postal Marie J.,
Chastang Claude
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900601)65:11<2435::aid-cncr2820651105>3.0.co;2-2
Subject(s) - medicine , vindesine , perioperative , randomized controlled trial , chemotherapy , surgery , randomization , bronchogenic carcinoma , carcinoma , cyclophosphamide , vincristine
In 1985, the authors began a phase II study to assess the PCV perioperative polychemotherapy (cisplatin 100 mg/m 2 , cyclophosphamide 600 mg/m 2 , vindesine 3 mg/m 2 ) in patients with resectable bronchogenic non‐small cell carcinoma. Patients were randomized to receive either two preoperative courses of PCV chemotherapy, surgery, and two postoperative courses of PCV chemotherapy (PCV group) or immediate surgery (surgery group). A staging procedure using the CT scan was performed before randomization and, additionally, before surgery in the PCV group. There were 26 randomized patients, 13 in each group. In the PCV group, 11 patients agreed to receive the two preoperative courses of chemotherapy. A response was observed in five patients (45%), and a progression was observed in four patients (36%) leading to a cancellation of surgery in two of them. Postoperative care was the same for each group. Although no death could be related to chemotherapy, it was decided to stop entering new patients into this trial because of the rate of preoperative progression in the PCV group.